Posluma Injection
NDC Package 69932-002-50
Package Information
Posluma (flotufolastat f-18) injection is pOSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy. This formulation utilizes a injection delivery system. Marketed by Blue Earth Diagnostics, this product is identified by NDC 69932-002 and is authorized under FDA application NDA216023.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 69932 - Blue Earth Diagnostics
- 69932-002 - Posluma
- 69932-002-50 - 25 mL in 1 VIAL, MULTI-DOSE
- 69932-002 - Posluma
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69932-002-50 identifies a specific commercial package of 25 ml in 1 vial, multi-dose of Posluma, a human prescription drug labeled by Blue Earth Diagnostics. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This injection is formulated for intravenous use and contains flotufolastat f-18 as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Blue Earth Diagnostics on May 25, 2023. The current certification is valid through December 31, 2026.
How is this Blue Earth Diagnostics product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69932000250. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
